Literature DB >> 15915461

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

David E Kleiner1, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida, Matthew Yeh, Arthur J McCullough, Arun J Sanyal.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P = .009), hepatocellular ballooning (P = .0001), lobular inflammation (P = .0001), fibrosis (P = .0001), and the absence of lipogranulomas (P = .001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of > or =5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."

Entities:  

Mesh:

Year:  2005        PMID: 15915461     DOI: 10.1002/hep.20701

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  2000 in total

1.  Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.

Authors:  Hussam Alamri; Nathan Heath Patterson; Ethan Yang; Pablo Zoroquiain; Anthoula Lazaris; Pierre Chaurand; Peter Metrakos
Journal:  Anal Bioanal Chem       Date:  2018-12-05       Impact factor: 4.142

2.  Enteric serotonin and oxytocin: endogenous regulation of severity in a murine model of necrotizing enterocolitis.

Authors:  Kara Gross Margolis; Jennifer Vittorio; Maria Talavera; Karen Gluck; Zhishan Li; Alina Iuga; Korey Stevanovic; Virginia Saurman; Narek Israelyan; Martha G Welch; Michael D Gershon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-08-03       Impact factor: 4.052

3.  Assessment of endothelial function in patients with nonalcoholic fatty liver disease.

Authors:  Yasar Colak; Ebubekir Senates; Atakan Yesil; Yusuf Yilmaz; Oguzhan Ozturk; Levent Doganay; Ender Coskunpinar; Ozlem Timirci Kahraman; Banu Mesci; Celal Ulasoglu; Ilyas Tuncer
Journal:  Endocrine       Date:  2012-06-03       Impact factor: 3.633

4.  Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.

Authors:  Geraldine J Ooi; Paul R Burton; Arul Earnest; Cheryl Laurie; William W Kemp; Peter D Nottle; Catriona A McLean; Stuart K Roberts; Wendy A Brown
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

5.  Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.

Authors:  Mohamed A Abdelmegeed; Atrayee Banerjee; Seong-Ho Yoo; Sehwan Jang; Frank J Gonzalez; Byoung-Joon Song
Journal:  J Hepatol       Date:  2012-06-02       Impact factor: 25.083

6.  Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis.

Authors:  Fabiola Rabelo; Claudia P M S Oliveira; Joel Faintuch; Daniel F C Mazo; Vicencia M R Lima; Jose Tadeu Stefano; Hermes V Barbeiro; Francisco G Soriano; Venancio A Ferreira Alves; Flair J Carrilho
Journal:  Obes Surg       Date:  2010-07       Impact factor: 4.129

7.  Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C.

Authors:  Sekou R Rawlins; Ola El-Zammar; J Michael Zinkievich; Nancy Newman; Robert A Levine
Journal:  Dig Dis Sci       Date:  2010-05-12       Impact factor: 3.199

8.  NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.

Authors:  Tarsila Ribeireiro; James Swain; Michael Sarr; Michael Kendrick; Florencia Que; Schuyler Sanderson; Anuradha Krishnan; Kimberly Viker; Kymberly Watt; Michael Charlton
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

Review 9.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

10.  Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease.

Authors:  Shikha S Sundaram; Ronald J Sokol; Kelley E Capocelli; Zhaoxing Pan; Jillian S Sullivan; Kristen Robbins; Ann C Halbower
Journal:  J Pediatr       Date:  2013-12-07       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.